Eli Lilly teams with Shaquille O’Neal to spotlight treating moderate obstructive sleep apnea with Zepbound (tirzepatide)

Eli Lilly and Company is launching a national campaign centered on basketball icon Shaquille O’Neal to raise awareness about obstructive sleep apnea (OSA) and the possibility of treatment. The company’s announcement, carried by Yahoo Finance, says O’Neal will describe living for years with moderate obstructive sleep apnea before learning it is treatable, positioning the story as a prompt for people who suspect they may have the condition to seek medical advice.

The campaign highlights O’Neal’s personal account as he discusses symptoms associated with OSA and the turning point that led him to pursue care. In the materials described in the coverage, the initiative is branded as Watch This, a reference to the idea that noticing what is happening during sleep and speaking with clinicians can be an important first step for diagnosis and management.

Eli Lilly is linking the campaign to Zepbound, its tirzepatide-based medicine. The coverage frames Zepbound within the message that addressing excess weight can be part of improving health outcomes for people with sleep apnea, though the post does not lay out clinical details such as specific trial results, endpoints, or the degree of symptom improvement. In addition, the reporting does not specify whether the campaign focuses on consumer awareness, prescriber education, or both.

The company’s choice of a widely recognized celebrity suggests a deliberate push toward broader public engagement around a medical condition that often goes undiagnosed. OSA is common and is typically associated with repeated episodes of upper-airway obstruction during sleep, which can contribute to daytime fatigue and other health risks when untreated. By using O’Neal’s story, Eli Lilly appears to be aiming to make the condition feel more understandable and less stigmatized.

While the announcement emphasizes O’Neal’s journey and the treatable nature of moderate OSA, it does not provide granular program information in the available reporting, such as the campaign’s media mix, timeline, or how clinicians are expected to incorporate the message into practice. It also does not state what specific claims are included about Zepbound in relation to sleep apnea beyond the general theme that treatment options exist.

The campaign arrives as Eli Lilly continues to build demand around its weight-management and metabolic portfolio. Zepbound, which contains tirzepatide, has become a focal product in the broader effort to treat obesity and weight-related conditions. Sleep apnea is frequently discussed in the same patient conversations as weight, making it a plausible target for awareness messaging that connects daily quality of life to ongoing medical management.

A caveat is that the available coverage does not disclose additional details that would normally help readers evaluate the campaign’s scope and the underlying evidence. The reporting does not mention specific data, regulatory references, or prescribing requirements tied to OSA, nor does it clarify whether any additional materials are being offered to consumers or healthcare professionals as part of Watch This.

Going forward, the key question for investors and observers is whether Lilly expands this kind of direct-to-public storytelling into additional campaigns tied to other conditions and whether regulators require modifications if promotional content is too broad. For the healthcare market, the immediate watch item is how quickly awareness efforts like this translate into greater attention to diagnosis and treatment discussions for OSA, particularly among patients who may not connect their symptoms to sleep apnea. Readers may also want to monitor what Lilly chooses to disclose in subsequent updates regarding messaging content and distribution.